

Pfizer Ltd

Ramsgate Road

Sandwich, Kent CT13 9NJ

United Kingdom

Revision date: 26-Oct-2009 Version: 1.2 Page 1 of 7

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

+00 44 (0)1304 616161

te number: Emergency telephone number:
rs): 1-800-424-9300 ChemSafe (24 hours): +44 (0)208 762 8322

Material Name: Clindamycin Phosphate Sterile Solution

Trade Name: DALACIN C; DALACIN; CLEOCIN

Chemical Family: Mixture

Intended Use: Pharmaceutical product used as antibiotic agent

2. HAZARDS IDENTIFICATION

Appearance: Clear, colorless solution

Signal Word: WARNING

Statement of Hazard: May cause allergic skin reaction.

Additional Hazard Information:

Short Term: Active ingredient may be harmful if swallowed. May cause eye irritation; May cause skin

irritation. (based on components) .

Known Clinical Effects: Individuals sensitive to this material or other materials in its chemical class may develop

allergic reactions. Clinical use of this drug has caused sore throat, fever, gastrointestinal disturbances, abnormal liver function tests, kidney dysfunction. Pseudomembranous colitis (manifested by watery diarrhea, urge to defecate, abdominal cramps, low-grade fever, bloody

stools, and abdominal pain) may also occur.

EU Indication of danger: Irritant

EU Hazard Symbols:



EU Risk Phrases:

Australian Hazard Classification (NOHSC):

R43 - May cause sensitization by skin contact. Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your

workplace.

Material Name: Clindamycin Phosphate Sterile Solution

Revision date: 26-Oct-2009 Version: 1.2

2. HAZARDS IDENTIFICATION

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	Classification	%	
Clindamycin Phosphate	24729-96-2	246-433-0	Xi;R36-43	15	
			Xn;R22		
			,		
Benzyl Alcohol	100-51-6	202-859-9	Xn;R20/22	<1.0	
Edetate disodium	139-33-3	205-358-3	Not Listed	<0.1	

Ingredient	CAS Number	EU EINECS/ELINCS List	Classification	%
Water for Injection	7732-18-5	231-791-2	Not Listed	*

Additional Information: * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

Page 2 of 7

safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. If irritation occurs or

persists, get medical attention.

Skin Contact: Remove contaminated clothing and wash exposed area with soap and water. Obtain medical

assistance if irritation occurs.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, sulfur oxides and other

sulfur-containing compounds.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Material Name: Clindamycin Phosphate Sterile Solution Page 3 of 7 Revision date: 26-Oct-2009 Version: 1.2

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill

area thoroughly.

Measures for Environmental

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

Additional Consideration for Large

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Avoid contact with eyes, skin and clothing. Wash thoroughly after handling.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Clindamycin Phosphate

Pfizer OEL TWA-8 Hr: 100µg/m³

Benzyl Alcohol

Bulgaria OEL - TWA Listed Czech Republic OEL - TWA Listed Latvia OEL - TWA Listed Lithuania OEL - TWA Listed **Poland OEL - TWA** Listed

Analytical Method: Analytical method available for clindamycin. Contact Pfizer Inc for further information. **Engineering Controls:**

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

Refer to specific Member State legislation for requirements under Community environmental **Environmental Exposure Controls:**

legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE).

Impervious gloves are recommended if skin contact with drug product is possible and for bulk Hands:

processing operations.

Wear safety glasses or goggles if eye contact is possible. Eyes:

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and

for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate

respirator with a protection factor sufficient to control exposures to below the OEL.

Page 4 of 7

Material Name: Clindamycin Phosphate Sterile Solution

Revision date: 26-Oct-2009 Version: 1.2

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:SolutionColor:Clear, colorlessMolecular Formula:MixtureMolecular Weight:Mixture

10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Clindamycin Phosphate

Rat Oral LD 50 1832 mg/kg
Rat Intravenous LD 50 321 mg/kg
Rat Intraperitoneal LD 50 745 mg/kg
Mouse Oral LD 50 2359 mg/kg
Mouse Intravenous LD 50 820 mg/kg

Benzyl Alcohol

Rat Oral LD50 1230 mg/kg Rat Intravenous LD50 53 mg/kg Rat Inhalation LC50 46 mg/m³

Edetate disodium

Rat Oral LD50 2000-2200 mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

Clindamycin Phosphate

Eye Irritation Rabbit Moderate Skin Irritation Rabbit Mild

Benzyl Alcohol

Eye Irritation Rabbit Severe
Skin Irritation Rabbit Moderate
Skin Irritation Guinea Pig Moderate

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Clindamycin Phosphate

6 Month(s) Rat Oral 600 mg/kg/day NOAEL No effects at maximum dose 6 Month(s) Dog Oral 600 mg/kg/day NOAEL Gastrointestinal system

Material Name: Clindamycin Phosphate Sterile Solution

Revision date: 26-Oct-2009 Version: 1.2

11. TOXICOLOGICAL INFORMATION

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Clindamycin Phosphate

Prenatal & Postnatal Development Rat Subcutaneous 250 mg/kg NOAEL Not teratogenic Prenatal & Postnatal Development Rat Oral 300 mg/kg/day NOAEL Not Teratogenic Prenatal & Postnatal Development Mouse Oral 600 mg/kg/day NOAEL Not Teratogenic

Prenatal & Postnatal Development Rabbit Subcutaneous 5 mg/kg/day NOAEL Not Teratogenic, Maternal Toxicity

Reproductive & Fertility Rat Oral 300 mg/kg/day NOAEL No effects at maximum dose

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Clindamycin Phosphate

Bacterial Mutagenicity (Ames) Salmonella Negative

In Vitro Micronucleus Rat Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment

should be avoided.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

Page 5 of 7

releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol: Xi EU Indication of danger: Irritant

EU Risk Phrases:

R43 - May cause sensitization by skin contact.

EU Safety Phrases:

S24 - Avoid contact with skin.

S36/37 - Wear suitable protective clothing and gloves.

Page 6 of 7

Material Name: Clindamycin Phosphate Sterile Solution

Revision date: 26-Oct-2009 Version: 1.2

15. REGULATORY INFORMATION

OSHA Label:

WARNING

May cause allergic skin reaction.

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision B



Water for Injection

Inventory - United States TSCA - Sect. 8(b)ListedAustralia (AICS):ListedREACH - Annex IV - Exemptions from thePresent

obligations of Register:

EU EINECS/ELINCS List 231-791-2

Clindamycin Phosphate

EU EINECS/ELINCS List 246-433-0

Benzyl Alcohol

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

202-859-9

Edetate disodium

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

205-358-3

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R22 - Harmful if swallowed.

R36 - Irritating to eyes.

R43 - May cause sensitization by skin contact. R20/22 - Harmful by inhalation and if swallowed.

Data Sources: Publicly available toxicity information. Safety data sheets for individual ingredients. Pfizer

proprietary drug development information.

Reasons for Revision: Updated Section 3 - Composition / Information on Ingredients. Updated Section 2 - Hazard

Identification. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section

13 - Disposal Considerations.

Page 7 of 7

Material Name: Clindamycin Phosphate Sterile Solution

Revision date: 26-Oct-2009 Version: 1.2

Prepared by: Toxicology and Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet